These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 402665)

  • 41. Effect of repeated administration of 11-hydroxy-delta 8-tetrahydrocannabinol, an active metabolite of delta 8-tetrahydrocannabinol, on the hepatic microsomal drug-metabolizing enzyme system of mice.
    Watanabe K; Arai M; Narimatsu S; Yamamoto I; Yoshimura H
    Biochem Pharmacol; 1986 Jun; 35(11):1861-5. PubMed ID: 3013200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delta 9-tetrahydrocannabinol sensitization of the rat brain to direct cholinergic stimulation.
    Duncan GE; Dagirmanjian R
    Psychopharmacology (Berl); 1979 Feb; 60(3):237-40. PubMed ID: 108700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
    Welch SP; Dunlow LD; Patrick GS; Razdan RK
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat.
    Whitlow CT; Freedland CS; Porrino LJ
    Psychopharmacology (Berl); 2002 May; 161(2):129-36. PubMed ID: 11981592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of drugs on behavior in pigeons tolerant to delta 9-tetrahydrocannabinol.
    McMillan DE; Leander JD; Dudley KH
    J Pharmacol Exp Ther; 1980 Jan; 212(1):85-90. PubMed ID: 7351628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Marihuana-like activity of new synthetic tetrahydrocannabinols.
    Martin BR; Dewey WL; Harris LS; Beckner J
    Pharmacol Biochem Behav; 1975; 3(5):849-53. PubMed ID: 1208625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Central excitatory properties of delta 9-tetrahydrocannabinol and its metabolites in iron-induced epileptic rats.
    Turkanis SA; Karler R
    Neuropharmacology; 1982 Jan; 21(1):7-13. PubMed ID: 6278353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of (-)-delta9-tetrahydrocannabinol on reserpine-induced hypothermia in rats.
    Englert LF; Ho BT; Taylor D
    Br J Pharmacol; 1973 Oct; 49(2):243-52. PubMed ID: 4793331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interactions between delta9-tetrahydrocannabinol and phencyclidine hydrochloride in rats.
    Pryor GT; Husain S; Larsen F; McKenzie CE; Carr JD; Braude MC
    Pharmacol Biochem Behav; 1977 Jan; 6(1):123-36. PubMed ID: 850686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats.
    Pryor GT; Larsen FF; Husain S; Braude MC
    Pharmacol Biochem Behav; 1978 Mar; 8(3):295-318. PubMed ID: 652837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man.
    Wall ME; Perez-Reyes M
    J Clin Pharmacol; 1981; 21(S1):178S-189S. PubMed ID: 6271823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain.
    Bonnin A; de Miguel R; Castro JG; Ramos JA; Fernandez-Ruiz JJ
    J Mol Neurosci; 1996; 7(4):291-308. PubMed ID: 8968950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity.
    Martin BR; Kallman MJ; Kaempf GF; Harris LS; Dewey WL; Razdan RK
    Pharmacol Biochem Behav; 1984 Jul; 21(1):61-5. PubMed ID: 6087379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats.
    Colasanti BK; Lindamood C; Craig CR
    Pharmacol Biochem Behav; 1982 Apr; 16(4):573-8. PubMed ID: 6280204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination.
    Zuardi AW; Karniol IG
    Braz J Med Biol Res; 1983 Jul; 16(2):141-6. PubMed ID: 6317104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Generalization of the discriminative stimulus properties of delta 9-THC to delta 9(11)-THC in rats.
    Semjonow A; Binder M
    Psychopharmacology (Berl); 1985; 85(2):178-83. PubMed ID: 2989965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adrenalectomy reverses the effects of delta-9-THC on mouse brain 5-hydroxytryptamine turnover.
    Johnson KM; Dewey WL; Bloom AS
    Pharmacology; 1981; 23(4):223-9. PubMed ID: 6275421
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
    Darmani NA
    Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
    Tsou K; Patrick SL; Walker JM
    Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.
    Rodríguez de Fonseca F; Gorriti MA; Fernández-Ruiz JJ; Palomo T; Ramos JA
    Pharmacol Biochem Behav; 1994 Jan; 47(1):33-40. PubMed ID: 8115426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.